Skip to contentL
Lisata Therapeutics, Inc.
L
LSTALisata Therapeutics, Inc. Released Mar 22, 2022, after the close
10-K filed Mar 22, 2022, 81 days after period end · 0000320017-22-000016
Q4 2020 · 10-K
derived · Computed from the longer spans the company filed.
Revenue—
Net Income-$6.79M-$6.79Mderived
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Lisata Therapeutics, Inc. · CIK 320017 · Engraved from SEC EDGAR
N/M vs Q3 2020
EPS, diluted—Not derived. Share counts vary by quarter.
Operating Incomederived-$6,849,000N/M Operating Cash Flowderived-$4,604,000N/M Free Cash Flowderived-$4,604,000N/M ended Dec 31, 2021 · filed Mar 22, 2022 · 81 d after period end